TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Intensified Treatment Regimens for TB Meningitis: PK, PD and Tolerability Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Tuberculous meningitis, diagnosed based on clinical and/or CSF criteria~* Age 15 years old or more~* Hospitalized for the treatment~Exclusion Criteria:~* Pregnancy/lactation~* On TB treatment within 7 days before inclusion~* Elevated liver enzyme (\> 5x than normal values)~* Known hypersensitivity/intolerance to rifampicin or moxifloxacin~* Prolonged QTc interval in ECG or other detectable cardiac arrythmias, in the absence of hypokalemia~* Refusal to be included in the study

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard dose rifampisin (Type: ACTIVE_COMPARATOR): Subjects in this arm receive 450 mg rifampicin orally.~In accordance with national TB treatment standard that encourages the use of 4 drugs, all subjects -both in active comparator and experimental arm- will also receive isoniazide 300 mg p.o. and pyrazinamide 1500 mg p.o.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)
- High dose rifampisin (Type: EXPERIMENTAL): Subjects in this arm receive 600 mg Rifampisin i.v. for 14 days, and the dosage will be switched to 450 mg Rifampisin p.o afterwards until completion of TB medication (in accordance with National TB Program)~In accordance with national TB treatment standard that encourages the use of 4 drugs, all subjects -both in active comparator and experimental arm- will also receive isoniazide 300 mg p.o. and pyrazinamide 1500 mg p.o.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: HD18 for Advanced Stages in Hodgkins Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Hodgkin Lymphoma (histologically proven)~* CS (PS) IIB with one or both of the risk factors:~  * bulky mediastinal mass (\> 1/3 of maximum transverse thorax diameter)~ * extranodal involvement~* CS (PS) III, IV~* Written informed consent~Exclusion Criteria:~* Leucocytes \< 3000/µl~* Platelets \< 100000/µl~* Hodgkin´s lymphoma as composite lymphoma~* Activity index (WHO) \< grade 2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): 8 cycles BEACOPPesc
- B (Type: EXPERIMENTAL): 8 cycles BEACOPPesc plus rituximab
- C (Type: ACTIVE_COMPARATOR): 8 cycles BEACOPPesc
- D (Type: EXPERIMENTAL): 4 cycles BEACOPPesc

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Autologous Adipose Tissue-Derived Mesenchymal Progenitor Cells (MPCs) Therapy for Knee Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. The subject is between 18-70 years of age, regardless of gender~2. The subject has a Kellgren-Lawrence grading, as determined by American College of Rheumatology (ACR) criteria for osteoarthritis of the knee, below grade 4~3. The subject or the subject's legally acceptable representative must be willing to participate in the trial, to receive cell therapy and to provide signed and dated informed consent forms~Exclusion Criteria:~1. The subject has an allergic history or is of an allergic constitution~2. The subject has uncontrolled or hard-to-control diseases of heart, liver, kidney or lung~3. The subject has uncontrolled or hard-to-control diseases of cardiovascular or endocrine system~4. The subject has severe infectious diseases or a malignant tumour~5. The subject has coagulation disorders~6. The subject has a BMI of over 30~7. The subject has used traditional Chinese medicine containing anti-inflammatory agents in the 2 weeks preceding the trial~8. The subject has received other intra-articular injections in the 2 months preceding the trial~9. The subject has complications or diseases of: systemic or rheumatoid arthritis, Chondrocalcinosis articular， Hemochromatosis，inflammatory arthropathy，avascular necrosis of femoral head，Paget's disease，hemophilic arthropathy，infectional arthritis，Charcot's disease，villonodular synovitis or synovial chondromatosis~10. The subject tests positive for: HIV, hepatitis virus, syphilis or other infectious diseases~11. The subject has a history of alcoholism, drug abuse, or mental illness~12. The subject has participated in any other clinical trial in the 3 months prior to this trial~13. The subject is pregnant, lactating or is planning to conceive within the next 6 months~14. The subject has any other unsuitable or adverse condition to be determined by the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Mesenchymal progenitor cells (Type: EXPERIMENTAL): Administrated for intra-articular use of Mesenchymal progenitor cells
- Sodium Hyaluronate (Type: ACTIVE_COMPARATOR): Administrated for intra-articular use of Sodium Hyaluronate.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Progression of Mild to Moderate Idiopathic Pulmonary Fibrosis (IPF) Under a Therapy With Esbriet® (Pirfenidone)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Adult patients with confident diagnosis of mild to moderate IPF, who had previously not yet been treated with Pirfenidone~Exclusion Criteria:~Hypersensitivity to the active substance or one of the other excipients of Pirfenidone Concomitant use of Fluvoxamin Severe hepatic impairment or end stage liver disease Severe renal impairment (Creatinine-Clearance \<30 ml/min) or end stage renal disease requiring dialysis Simultaneous participation in interventional studies Previously treated with Pirfenidone for longer than 30 days

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Participants with idiopathic pulmonary fibrosis (Type: None): Participants with idiopathic pulmonary fibrosis receiving Pirfenidone will be observed for treatment responses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Age \> 18 years old~* HIV-2 Infection (confirmed by DetermineTM \& Immunocomb II)~* ARV-naïve~* CD4 count \< 750 cells/mm3 and/or WHO Stage 3 or 4 disease~* Anticipate residing in Dakar area for duration of study~Exclusion Criteria:~* Pregnancy or Breast feeding~* HIV-1 or HIV-1/HIV-2 dual infection~* Known allergy or contraindication to Elvitegravir, Cobicistat, Emtricitabine, or Tenofovir DF~* Active Tuberculosis (STRIBILD contraindicated with rifampin)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open label prospective single arm study of Stribild (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients less than 16 years old with newly diagnosed PML-RARa positive acute promyelocytic leukemia.~Exclusion Criteria:~* Patients who have coma, convulsion or paralysis due to intracranial hemorrhage or central nervous system leukemia at diagnosis.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- ATO and chemotherapy (Type: ACTIVE_COMPARATOR): Induction:~ATRA 25mg/m2 d1-CR ≯42 days; ATO 0.16mg/kg d5-CR ≯42 days; mitoxantrone (MA) 10mg/m2 d3, or 7mg/m2 d2-4 (high risk).~Consolidation 1:~ATRA 25mg/m2 d1-15; MA 10mg/m2 d1-2; Intrathecal injection (IT)：Ara-C 15mg (age \< 1 year), or 20 mg (1-3 years), or 30 mg ( \> 3 years), dexamethasone 2mg.~Consolidation 2:~ATRA 25mg/m2 d1-15; ATO 0.16mg/kg d1-15; Ara-C 1g/m2 q12h d1-2 (high risk); IT.~Consolidation 3:~ATRA 25mg/m2 d1-15; ATO 0.16mg/kg d1-15; MA 10mg/m2 d1; Ara-C 1g/m2 q12h d1-2 (high risk); IT.~Maintenance:~① ATO 0.16mg/kg.d w1-2; ATRA 25mg/m2.d w1-2; MTX 20mg/m2 qw w3-12; 6MP 50mg/m2 qn w3-12. ② ATRA 25mg/m2.d w1-2; MTX 20mg/m2 qw w3-12; 6MP 50mg/m2 qn w3-12. Rotation between ① and ② until the end of maintenance.
- RIF and chemotherapy (Type: EXPERIMENTAL): Induction:~ATRA 25mg/m2 d1-CR ≯42 days; RIF 0.135/kg d5-CR ≯42 days; mitoxantrone (MA) 10mg/m2 d3, or 7mg/m2 d2-4 (high risk).~Consolidation 1:~ATRA 25mg/m2 d1-15; MA 10mg/m2 d1-2; Intrathecal injection (IT)：Ara-C 15mg (age \< 1 year), or 20mg (age 1-3 years), or 30mg (age \> 3 years), dexamethasone 2mg.~Consolidation 2:~ATRA 25mg/m2 d1-15; RIF 0.135/kg d1-15; Ara-C 1g/m2 q12h d1-2 (high risk); IT.~Consolidation 3:~ATRA 25mg/m2 d1-15; RIF 0.135/kg d1-15; MA 10mg/m2 d1; Ara-C 1g/m2 q12h d1-2 (high risk); IT.~Maintenance:~① RIF 0.135/kg.d w1-2; ATRA 25mg/m2.d w1-2; MTX 20mg/m2 qw w3-12; 6MP 50mg/m2 qn w3-12. ② ATRA 25mg/m2.d w1-2; MTX 20mg/m2 qw w3-12; 6MP 50mg/m2 qn w3-12. Rotation between ① and ② until the end of maintenance treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Tolerability, and Safety of DFN-15

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. A history of episodic migraine, who experience 2 to 8 migraine attacks per month for at least the past 12 months, with no more than 14 headache days per month, and with 48 hours of headache-free time between migraine attacks.~2. Patients who have migraine with or without aura with onset before age 50 years~3. Report usual migraine pain of 2 (moderate) or 3 (severe) on headache pain severity scale without treatment.~4. Subjects who are willing and able to:~   1. Evaluate and record pain, migraine symptoms, and study drug effectiveness information in real-time using a subject eDiary for the duration of the study;~  2. Record each instance of the use of study drug and rescue medication in real-time using a subject eDiary for the duration of the study;~  3. Comply with all other study procedures and scheduling requirements.~Exclusion Criteria:~1. Minors, even if they are in the specified study age range~2. Medication overuse:~   1. Opioids greater than or equal to 10 days during the 90 days prior to screening~  2. Combination medications (e.g., Fiorinal®) greater than or equal to 10 days during the 90 days prior to screening (applies only if includes opioid and/or barbiturate)~  3. Nonsteroidal Anti-inflammatory Drugs or other simple medications greater than 14 days a month during the 90 days prior to screening~  4. Triptans or ergots greater than or equal to 10 days a month during the 90 days prior to screening~3. Treated with onabotulinumtoxin A (Botox®) for migraine within 4 months prior to screening. (If treated for cosmetic reasons, subjects may be included).~4. Current treatment with antipsychotics or use of antipsychotics within 30 days prior to randomization.~5. Patients who have received treatment with an investigational drug or device within 30 days of randomization, or participated in a central nervous system clinical trial within 2 months prior to randomization~6. Patients with positive screening test for human immunodeficiency virus \[HIV\], positive hepatitis B surface antigen (HBsAg), or positive hepatitis C virus \[HCV\] antibody~7. Subjects who are employees or immediate relatives of the employees of the Sponsor, any of its affiliates or partners, or of the clinical research study site.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- DFN-15 Active (Type: EXPERIMENTAL): DFN-15 Active
- DFN-15 Placebo (Type: PLACEBO_COMPARATOR): DFN-15 Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mesenchymal Stem Cells in Knee Cartilage Injuries

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* MRI must show moderate/severe articular injury~* Serum collagen II must be above the normal value.~* Lesion site: Femoral and Tibial condyles or patella~* Admission of steroid , NSAID, pain killers must be stopped before 1 month~Exclusion Criteria:~* Lesion size~* PT and PTT not within normal value~* Complete blood count ( Hb, PCV, and RBC) not within the normal value~* HIV and Hepatitis Antigens (B and C) detection

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 68 Years
- Healthy Volunteers: f

Study Arms:
- mesenchymal stem cells (Type: ACTIVE_COMPARATOR): Autologous Mesenchymal Stem Cells primed prior to intra articular injection into knees of patients with advanced articular cartilage injury
- mesenchymal cells&platelet lysate (Type: ACTIVE_COMPARATOR): Autologous Mesenchymal Stem Cells primed prior to intra articular injection with platelet lysate into knees of patients with advanced articular cartilage injury

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Multiple Attacks of Acute Migraine (0462-025)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patient had at least a 6-month history of migraine, with or without aura~* Patient was male, or if female must have been postmenopausal, surgically sterilized, or taking adequate contraceptive precautions.~* Patient was judged to be in good health, apart from migraine~Exclusion Criteria:~* Patient was pregnant or a nursing mother.~* Patient had abused drugs or alcohol within 12 months prior to entering the study~* Patient had a history of cardiovascular disease~* Patient had clinically significant ECG abnormality~* Patient had a resting systolic blood pressure of greater than 145 mm Hg or diastolic of less than 95 mm Hg at screening~* Patient received treatment with an investigational device or compound within 30 days of the study start~* Patient typically suffered from less then 1 or more than 8 attacks of migraine per month~* Patient had difficulty in distinguishing his/her migraine attacks from tension or interval headaches~* Patient had prior exposure to rizatriptan

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Sequence 1 (Type: EXPERIMENTAL): Placebo-Rizatriptan-Rizatriptan-Rizatriptan
- Treatment Sequence 2 (Type: EXPERIMENTAL): Rizatriptan-Placebo-Rizatriptan-Rizatriptan
- Treatment Sequence 3 (Type: EXPERIMENTAL): Rizatriptan-Rizatriptan-Placebo-Rizatriptan
- Treatment Sequence 4 (Type: EXPERIMENTAL): Rizatriptan-Rizatriptan-Rizatriptan-Placebo
- Treatment Sequence 5 (Type: EXPERIMENTAL): Rizatriptan-Rizatriptan-Rizatriptan-Rizatriptan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical and Molecular Phenotyping in IBD

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* inflammatory bowel disease~* indication for biological therapy~Exclusion Criteria:~* pregnancy, breast feeding~* no written informed consent to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Infliximab (Type: ACTIVE_COMPARATOR): 5 mg/kg body weight, week 0/2/6, then every 8 weeks
- Vedolizumab (Type: ACTIVE_COMPARATOR): 300 mg, week 0/2/6, then every 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Exploratory stuDy of effectIveneSs and Safety of rivarOxaban in Patients With Left VEntricular Thrombus (R-DISSOLVE)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients over 18 years old;~2. Patients with left ventricular thrombus newly found by body surface ultrasound less than or equal to 3 months before selection, with no limitation on basic diseases;~3. Patients who received standard anticoagulant therapy for less than 4 weeks before enrollment did not use antiplatelet drugs or only used single antiplatelet drugs;~4. The patients voluntarily joined the study and signed the informed consent.~Exclusion Criteria:~1. Patients with contraindications to rivaroxaban anticoagulation therapy;~2. Patients with a history of acute pulmonary embolism or deep venous thrombosis within a week need intensive anticoagulant therapy;~3. Patients with history of hemorrhagic stroke within one week;~4. Patients with cardiac benign and malignant tumors;~5. Aspirin and P2Y12 receptor antagonists should be kept;~6. In patients with severe hepatic and renal insufficiency, alanine aminotransferase \> 3 times the upper limit and total bilirubin \> 2 times the upper limit, creatinine clearance rate \< 15ml / min / 1.73m2;~7. The patient's history of intracerebral hemorrhage and active hemorrhage was 8 months;~8. Patients with hematological diseases, hemoglobin \< 100g / L, platelet \< 80 x 10\^9 / L;~9. Women with pregnancy status, planned pregnancy and lactation period;~10. Patients with life expectancy less than 1 year;~11. Patients enrolled in other clinical studies;~12. Other situations considered unsuitable by the researcher. Note: anticoagulant therapy can be given to patients with left ventricular thrombosis combined with hemorrhagic stroke ≥ 4 weeks or recent ischemic stroke / transient ischemic attack according to the specific situation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban (Type: EXPERIMENTAL): Rivaroxaban: Patients with ventricular mural thrombus in the study receive rivaroxaban anticoagulant therapy for 12 weeks. The dosage of rivaroxaban was typically 20mg once daily, or 15mg once daily if patients were on dual antiplateletagents, or with creatinine clearance of 30-50mL/min.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete